Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 132.0122
- Book/Share 275.4227
- PB 2.0324
- Debt/Equity 0.092
- CurrentRatio 4.9267
- ROIC 0.1024
- MktCap 59417404480.0
- FreeCF/Share 28.3046
- PFCF 19.674
- PE 13.2746
- Debt/Assets 0.072
- DivYield 0.0031
- ROE 0.1477
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
| Resumed | REGN | Cantor Fitzgerald | -- | Overweight | -- | $695 | April 22, 2025 |
| Upgrade | REGN | Leerink Partners | Market Perform | Outperform | $762 | $834 | Feb. 5, 2025 |
| Downgrade | REGN | UBS | Buy | Neutral | $1130 | $738 | Jan. 16, 2025 |
| Resumed | REGN | BofA Securities | -- | Underperform | -- | $565 | Dec. 10, 2024 |
| Downgrade | REGN | Leerink Partners | Outperform | Market Perform | $1175 | $1077 | Sept. 24, 2024 |
News
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.
Read More
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
Read More
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
Published: July 02, 2025 by: WSJ
Sentiment: Positive
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
Read More
US FDA approves Regeneron's blood cancer therapy
Published: July 02, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.
Read More
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Read More
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
Published: June 11, 2025 by: CNBC Television
Sentiment: Neutral
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and more.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Read More
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
Read More
Why Regeneron Is Falling And Why You Should Avoid It
Published: June 04, 2025 by: Benzinga
Sentiment: Negative
Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.
Read More
REGN Stock Undervalued At $500?
Published: June 02, 2025 by: Forbes
Sentiment: Negative
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.
Read More
Regeneron's weight-loss drug helps preserve muscle mass in study
Published: June 02, 2025 by: Reuters
Sentiment: Positive
Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.
Read More
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China
Read More
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
Published: May 30, 2025 by: Investopedia
Sentiment: Neutral
Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April.
Read More
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
Published: May 30, 2025 by: Market Watch
Sentiment: Negative
Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.
Read More
Itepekimab Failure A Setback For Sanofi And Regeneron
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.
Read More
Regeneron shares plunge after mixed COPD drug trial results
Published: May 30, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in two Phase 3 trials—casting doubt on its regulatory path and delaying hopes for a major new revenue stream. The drug, itepekimab, reduced moderate or severe flare-ups by 27% compared to placebo over 52 weeks in the AERIFY-1 study, which enrolled 1,127 former smokers with chronic obstructive pulmonary disease (COPD).
Read More
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Read More
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).
Read More
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosimilars entered the market, stalling overall company growth. Dupixent continues strong growth with new approvals in COPD and CSU, keeping Regeneron profitable despite challenges.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.
Read More
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
Read More
Regeneron Buys 23andMe in Bankruptcy Auction
Published: May 19, 2025 by: Investopedia
Sentiment: Negative
Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
Read More
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
Published: May 19, 2025 by: New York Post
Sentiment: Negative
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.
Read More
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Published: May 19, 2025 by: Fox Business
Sentiment: Neutral
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
Read More
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
Published: May 19, 2025 by: TechCrunch
Sentiment: Neutral
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.
Read More
Cramer's Stop Trading: Regeneron
Published: May 19, 2025 by: CNBC Television
Sentiment: Neutral
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
Read More
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Published: May 19, 2025 by: CNBC
Sentiment: Neutral
Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health and Research Services business lines, but not its telehealth subsidiary Lemonaid Health.
Read More
Regeneron to buy 23andMe out of bankruptcy for $256m
Published: May 19, 2025 by: Proactive Investors
Sentiment: Neutral
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes 23andMe's consumer DNA testing and health research services, but excludes its telehealth arm, Lemonaid Health, which is being shut down.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158